Latest On Rigel Pharmaceuticals, Inc (RIGL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 15:54 EST | News | Rigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive Growth | N/A |  |
| 2023-05-03 02:14 EST | News | Rigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.02, revenue of $26.07M beats by $2M | N/A | |
| 2023-05-03 02:13 EST | News | Rigel Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-03 02:13 EST | News | Rigel Pharmaceuticals, Inc. (RIGL) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-02 01:42 EST | News | Rigel Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-04-27 09:21 EST | News | Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability | N/A | |
| 2023-04-04 02:31 EST | News | Rigel Pharma begun at neutral at Piper Sandler on value creation potential | N/A | |
| 2023-03-09 06:02 EST | News | Rigel Pharmaceuticals' Challenges Continue To Outweigh Potential Upside | N/A | |
| 2023-03-08 00:02 EST | News | Rigel Pharma, with beats on quarterly top and bottom lines, surges 19% | N/A | |
| 2023-03-08 00:02 EST | News | Rigel Pharmaceuticals GAAP EPS of $0.34 beats by $0.80, revenue of $120.24M beats by $27.04M | N/A | |
| 2023-03-08 00:02 EST | News | Rigel Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2023-03-08 00:02 EST | News | Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-06 18:38 EST | News | Rigel Pharmaceuticals Q4 2022 Earnings Preview | N/A | |
| 2023-01-28 01:25 EST | News | Rigel Pharmaceuticals (RIGL) Investor Presentation - Slideshow | N/A | |
| 2023-01-09 20:04 EST | News | Rigel Pharma rises as preliminary Q4 revenue above estimates | N/A | |
| 2022-12-31 03:48 EST | News | Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023 | N/A | |
| 2022-12-22 20:32 EST | News | Rigel launches leukemia therapy in U.S. | N/A | |
| 2022-12-15 15:09 EST | News | Rigel extends gains as dosing starts in early-stage trial for blood cancer therapy | N/A | |
| 2022-12-03 04:05 EST | News | Rigel upgraded at Citi on bullish outlook for new leukemia drug | N/A | |
| 2022-12-02 10:34 EST | News | Rigel stock soars 40% on FDA approval of blood cancer drug Rezlidhia | N/A | |
| 2022-11-04 07:46 EST | News | Rigel Pharmaceuticals GAAP EPS of -$0.11 beats by $0.03, revenue of $22.4M misses by $0.21M | N/A | |
| 2022-11-04 07:46 EST | News | Rigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-04 07:46 EST | News | Rigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-02 22:35 EST | News | Rigel Pharma gains as analysts play down setback for COVID-19 therapy | N/A | |
| 2022-10-31 23:15 EST | News | Rigel Pharmaceuticals Provides An Opportunity For Investors Or An Acquirer | N/A | |
| 2022-10-11 06:01 EST | News | Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib | N/A | |
| 2022-08-18 23:47 EST | News | Rigel Pharma adds ~7% to reach over two month high | N/A | |
| 2022-08-04 01:22 EST | News | Rigel rises 17% on strong Q2 result | N/A | |
| 2022-08-03 10:19 EST | News | Rigel Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-03 10:19 EST | News | Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-02 20:22 EST | News | Rigel Pharmaceuticals GAAP EPS of -$0.08 beats by $0.04, revenue of $29.82M beats by $6.17M | N/A | |
| 2022-08-02 05:27 EST | News | Rigel Pharmaceuticals Q2 2022 Earnings Preview | N/A | |
| 2022-06-10 02:16 EST | News | Rigel Pharma downgraded at several street firms following anemia study failure | N/A | |
| 2022-06-09 00:09 EST | News | Rigel stock crashes 48% as fostamatinib fails phase 3 anemia study | N/A | |
| 2022-06-09 00:08 EST | News | Rigel cut to Neutral at Cantor Fitzgerald after trial miss wipes out half of stock value | N/A | |
| 2022-05-31 10:56 EST | News | Rigel Pharmaceuticals: A Status Check | N/A | |
| 2022-05-04 11:44 EST | News | Rigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-03 19:55 EST | News | Rigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8M | N/A | |
| 2022-05-03 19:54 EST | News | Rigel Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-03 01:40 EST | News | Rigel Pharmaceuticals Q1 2022 Earnings Preview | N/A | |
| 2022-04-08 20:19 EST | News | Rigel Pharmaceuticals grants stock options to employees | N/A | |
| 2022-03-22 02:13 EST | News | Rigel Pharmaceuticals: Why The Stock Is On A Run | N/A | |
| 2022-03-02 05:58 EST | News | Rigel Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $20.41M misses by $0.79M | N/A | |
| 2022-03-02 05:58 EST | News | Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-02 05:58 EST | News | Rigel Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-02-28 17:57 EST | News | Rigel Pharmaceuticals Q4 2021 Earnings Preview | N/A | |
| 2022-02-01 13:56 EST | News | Rigel Pharmaceuticals: A Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net | N/A | |
| 2022-01-11 00:53 EST | News | Rigel down as it expects slight decrease in products sales in Q4 compared to prior year | N/A | |
| 2021-12-22 03:23 EST | News | Rigel Pharma says its trial for bleeding disorder therapy met main goal in Japan | N/A | |
| 2021-11-30 10:44 EST | News | Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive | N/A | |
About Rigel Pharmaceuticals, Inc (RIGL):
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
General
- Name Rigel Pharmaceuticals, Inc
- Symbol RIGL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 169
- Last Split Factor1:9
- Last Split Date2003-06-25
- Fiscal Year EndDecember
- IPO Date2000-11-29
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.rigel.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 6.34
- Price/Book (Most Recent Quarter) 20.39
- Enterprise Value Revenue 6.22
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.02
- Next Year EPS Estimate -$0.20
- Next Quarter EPS Estimate -$0.03
- Profit Margin -27%
- Operating Margin -27%
- Return on Assets -14%
- Return on Equity -68%
- Revenue 108.62 million
- Earnings Per Share -$0.35
- Revenue Per Share $0.64
- Gross Profit 47.63 million
- Quarterly Earnings Growth 19.8%
View More
Highlights
- Market Capitalization 689.52 million
- EBITDA -60896000
- PE Ratio -7.76
- PEG Ratio -0.1
- Analyst Target Price $8.5
- Book Value Per Share $0.20
View More
Share Statistics
- Shares Outstanding 170.04 million
- Shares Float 169.52 million
- % Held by Insiders 31%
- % Held by Institutions 85.26%
- Shares Short 16.81 million
- Shares Short Prior Month 19.36 million
- Short Ratio 3.15
- Short % of Float 11%
- Short % of Shares Outstanding 10%
View More
Technicals
- Beta 1.45
- 52 Week High $5.5
- 52 Week Low $1.26
- 50 Day Moving Average 4.2
- 200 Day Moving Average 3.23
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Rigel Pharmaceuticals, Inc (RIGL) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Rigel Pharmaceuticals, Inc (RIGL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-02 | $18.45 million | -$0.11 | -$0.11 | 3.51% |
| 2020-09-30 | 2020-11-05 | $18.39 million | -$0.08 | -$0.12 | 34.05% |
| 2020-06-30 | 2020-08-04 | $16.02 million | -$0.10 | -$0.14 | 26.09% |
| 2020-03-31 | 2020-05-05 | $55.76 million | $0.13 | $0.13 | -1.59% |
| 2019-12-31 | 2020-02-27 | $15.4 million | -$0.10 | -$0.12 | 17.56% |
| 2019-09-30 | 2019-11-05 | $20.86 million | -$0.07 | -$0.10 | 32.69% |
| 2019-06-30 | 2019-08-06 | $10.41 million | -$0.12 | -$0.14 | 12.22% |
| 2019-03-31 | 2019-05-07 | $12.62 million | -$0.11 | -$0.13 | 15.38% |
| 2018-12-31 | 2019-02-28 | $37.86 million | $0.02 | $0.03 | -41.35% |
| 2018-09-30 | 2018-11-06 | $4.87 million | -$0.14 | -$0.15 | 7.83% |
| 2018-06-30 | 2018-08-08 | $1.79 million | -$0.16 | -$0.16 | -0.19% |
| 2018-03-31 | 2018-05-01 | $N/A | -$0.17 | -$0.18 | 3.41% |
| 2017-12-31 | 2018-03-06 | $3.58 million | -$0.18 | -$0.13 | -35.03% |
| 2017-09-30 | 2017-11-07 | $900000 | -$0.14 | -$0.15 | 8.32% |
| 2017-06-30 | 2017-08-01 | $-3584000 | -$0.16 | -$0.14 | -12.76% |
| 2017-03-31 | 2017-05-02 | $3.58 million | -$0.13 | -$0.12 | -5.18% |
| 2016-12-31 | 2017-03-07 | $3 million | -$0.16 | -$0.17 | 5.33% |
| 2016-09-30 | 2016-11-01 | $3.76 million | -$0.24 | -$0.23 | -3.99% |
| 2016-06-30 | 2016-08-02 | $8.59 million | -$0.15 | -$0.20 | 26.33% |
| 2016-03-31 | 2016-05-03 | $5.03 million | -$0.19 | -$0.21 | 9.18% |
| 2015-12-31 | 2016-03-08 | $8.54 million | -$0.14 | -$0.14 | -3.47% |
| 2015-09-30 | 2015-11-03 | $13 million | -$0.08 | -$0.17 | 52.94% |
| 2015-06-30 | 2015-08-04 | $5.18 million | -$0.16 | -$0.22 | 27.27% |
| 2015-03-31 | 2015-05-07 | $2.18 million | -$0.21 | -$0.18 | -16.67% |
| 2014-12-31 | 2015-03-03 | $8.25 million | -$0.15 | -$0.26 | 42.31% |
| 2014-09-30 | 2014-11-04 | $N/A | -$0.24 | -$0.27 | 11.11% |
| 2014-06-30 | 2014-08-05 | $N/A | -$0.29 | -$0.25 | -16% |
| 2014-03-31 | 2014-05-07 | $N/A | -$0.25 | -$0.25 | 0% |
| 2013-12-31 | 2014-03-04 | $5.75 million | -$0.19 | -$0.25 | 24% |
| 2013-09-30 | 2013-11-05 | $-1400000 | -$0.25 | -$0.29 | 13.79% |
| 2013-06-30 | 2013-08-06 | $1.4 million | -$0.26 | -$0.30 | 13.33% |
| 2013-03-31 | 2013-05-07 | $N/A | -$0.29 | -$0.30 | 3.33% |
| 2012-12-31 | 2013-03-05 | $2.25 million | -$0.30 | -$0.32 | 6.25% |
| 2012-09-30 | 2012-11-06 | $-1500000 | -$0.36 | -$0.37 | 2.7% |
| 2012-06-30 | 2012-08-07 | $1.5 million | -$0.35 | -$0.35 | 0% |
| 2012-03-31 | 2012-05-01 | $750000 | -$0.32 | -$0.31 | -3.23% |
| 2011-12-31 | 2012-03-06 | $395000 | -$0.36 | -$0.28 | -28.57% |
| 2011-09-30 | 2011-11-01 | $4.36 million | -$0.25 | -$0.30 | 16.67% |
| 2011-06-30 | 2011-08-02 | $395000 | -$0.37 | -$0.38 | 2.63% |
| 2011-03-31 | 2011-05-03 | $N/A | -$0.40 | -$0.36 | -11.11% |
| 2010-12-31 | 2011-03-01 | $52.72 million | -$0.33 | -$0.36 | 8.33% |
| 2010-09-30 | 2010-11-02 | $72.28 million | $0.96 | $0.62 | 54.84% |
| 2010-06-30 | 2010-08-03 | $49.46 million | $0.51 | $0.47 | 8.51% |
| 2010-03-31 | 2010-05-04 | $3.26 million | -$0.43 | $0.11 | -490.91% |
| 2009-12-31 | 2010-03-02 | $750000 | -$0.48 | -$0.45 | -6.67% |
| 2009-09-30 | 2009-11-03 | $N/A | -$0.70 | -$0.58 | -20.69% |
| 2009-06-30 | 2009-08-04 | $N/A | -$0.81 | -$0.81 | 0% |
| 2009-03-31 | 2009-05-05 | $N/A | -$0.82 | -$0.99 | 17.17% |
| 2008-12-31 | 2009-02-24 | $N/A | -$0.91 | -$0.97 | 6.19% |
| 2008-09-30 | 2008-11-03 | $N/A | -$1.03 | -$0.87 | -18.39% |
| 2008-06-30 | 2008-08-05 | $N/A | -$0.93 | -$0.69 | -34.78% |
| 2008-03-31 | 2008-05-06 | $N/A | -$0.79 | -$0.62 | -27.42% |
| 2007-12-31 | 2008-02-12 | $8 million | -$0.61 | -$0.43 | -41.86% |
| 2007-09-30 | 2007-11-06 | $-1956000 | -$0.61 | -$0.57 | -7.02% |
| 2007-06-30 | 2007-08-07 | $1.96 million | -$0.68 | -$0.63 | -7.94% |
| 2007-03-31 | 2007-05-10 | $2.64 million | -$0.68 | -$0.67 | -1.49% |
| 2006-12-31 | 2007-02-06 | $3.13 million | -$0.62 | -$0.64 | 3.13% |
| 2006-09-30 | 2006-11-07 | $6.13 million | -$0.46 | -$0.47 | 2.13% |
| 2006-06-30 | 2006-08-02 | $14.32 million | -$0.09 | -$0.56 | 83.93% |
| 2006-03-31 | 2006-05-02 | $9.9 million | -$0.34 | -$0.32 | -6.25% |
| 2005-12-31 | 2006-02-07 | $6.02 million | -$0.36 | -$0.43 | 16.28% |
| 2005-09-30 | 2005-11-08 | $3.28 million | -$0.56 | -$0.61 | 8.2% |
| 2005-06-30 | 2005-08-03 | $4.61 million | -$0.62 | -$0.71 | 12.68% |
| 2005-03-31 | 2005-05-03 | $2.62 million | -$0.57 | -$0.48 | -18.75% |
| 2004-12-31 | 2005-02-08 | $1.1 million | -$0.75 | -$0.69 | -8.7% |
| 2004-09-30 | 2004-11-05 | $659000 | -$0.88 | -$0.71 | -23.94% |
| 2004-06-30 | 2004-08-03 | $1.49 million | -$0.68 | -$0.74 | 8.11% |
| 2004-03-31 | 2004-05-04 | $1.49 million | -$0.81 | -$0.78 | -3.85% |
| 2003-12-31 | 2004-02-03 | $2.11 million | -$0.80 | -$0.71 | -12.68% |
| 2003-09-30 | 2003-11-05 | $2.1 million | -$0.78 | ||
| 2003-06-30 | 2003-08-05 | $2.35 million | -$1.90 | ||
| 2003-03-31 | 2003-05-06 | $4.5 million | -$1.53 | ||
| 2002-12-31 | 2003-02-05 | $3.7 million | -$1.62 | -$2.16 | 25% |
| 2002-09-30 | 2002-11-04 | $3.65 million | -$1.98 | -$1.80 | -10% |
| 2002-06-30 | 2002-08-06 | $4.34 million | -$2.07 | -$1.35 | -53.33% |
| 2002-03-31 | 2002-05-07 | $4.1 million | -$1.71 | -$1.53 | -11.76% |
| 2001-12-31 | 2002-02-05 | $4.78 million | -$1.44 | -$1.84 | 21.74% |
| 2001-09-30 | 2001-11-07 | $4.21 million | -$1.53 | -$1.53 | 0% |
| 2001-06-30 | 2001-08-08 | $3.12 million | -$1.80 | -$0.99 | -81.82% |
| 2001-03-31 | 2001-05-08 | $3.19 million | -$0.99 | -$1.44 | 31.25% |
| 2000-12-31 | 2001-02-07 | $3.21 million | -$3.24 | -$2.34 | -38.46% |
Rigel Pharmaceuticals, Inc (RIGL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Rigel Pharmaceuticals, Inc (RIGL) Chart:
Rigel Pharmaceuticals, Inc (RIGL) News:
Below you will find a list of latest news for Rigel Pharmaceuticals, Inc (RIGL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Rigel Pharmaceuticals, Inc (RIGL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 0.5 | 0 | CALL | 0 | 0 | 469.19 | TRUE | 0 | 0 |
| 2024-05-17 | 1 | 0.25 | CALL | 0 | 11 | 130.24 | TRUE | 0 | 0 |
| 2024-05-17 | 1.5 | 0.06 | CALL | 0 | 65 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2 | 0.05 | CALL | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 4 | 0.06 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.01 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0.06 | PUT | 0 | 101 | 111 | FALSE | 0 | 0 |
| 2024-05-17 | 1.5 | 0 | PUT | 0 | 0 | 63.16 | TRUE | 0 | 0 |
| 2024-05-17 | 2 | 0 | PUT | 0 | 0 | 263.74 | TRUE | 0 | 0 |
| 2024-05-17 | 3 | 0 | PUT | 0 | 0 | 570.24 | TRUE | 0 | 0 |
| 2024-05-17 | 4 | 0 | PUT | 0 | 0 | 447.73 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 578.59 | TRUE | 0 | 0 |
| 2024-06-21 | 0.5 | 0 | CALL | 0 | 0 | 250.03 | TRUE | 0 | 0 |
| 2024-06-21 | 1 | 0.24 | CALL | 4 | 992 | 124.99 | TRUE | 0.24 | 0 |
| 2024-06-21 | 1.5 | 0.1 | CALL | 0 | 184 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2 | 0.06 | CALL | 0 | 2215 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 3 | 0.03 | CALL | 5 | 1138 | 161.87 | FALSE | -0.02 | -0.4 |
| 2024-06-21 | 4 | 0.05 | CALL | 0 | 20 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0.01 | CALL | 0 | 6 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 0.5 | 0.19 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1 | 0.07 | PUT | 0 | 188 | 90.58 | FALSE | 0 | 0 |
| 2024-06-21 | 1.5 | 0.35 | PUT | 0 | 17 | 134.61 | TRUE | 0 | 0 |
| 2024-06-21 | 2 | 0.55 | PUT | 0 | 4 | 180.14 | TRUE | 0 | 0 |
| 2024-06-21 | 3 | 1.55 | PUT | 0 | 1 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 4 | 0 | PUT | 0 | 0 | 273.03 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 511.94 | TRUE | 0 | 0 |
| 2024-09-20 | 0.5 | 0.99 | CALL | 0 | 2 | 236.65 | TRUE | 0 | 0 |
| 2024-09-20 | 1 | 0.35 | CALL | 1 | 163 | 122.07 | TRUE | 0.35 | 0 |
| 2024-09-20 | 1.5 | 0.2 | CALL | 0 | 505 | 99.31 | FALSE | 0 | 0 |
| 2024-09-20 | 2 | 0.07 | CALL | 0 | 2981 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 3 | 0.05 | CALL | 0 | 3038 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 4 | 0.05 | CALL | 0 | 112 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 5 | 0.05 | CALL | 0 | 19 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 0.5 | 0.04 | PUT | 0 | 10 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 1 | 0.15 | PUT | 0 | 57 | 79.89 | FALSE | 0 | 0 |
| 2024-09-20 | 1.5 | 0.45 | PUT | 0 | 31 | 90.52 | TRUE | 0 | 0 |
| 2024-09-20 | 2 | 0.7 | PUT | 0 | 11 | 150.6 | TRUE | 0 | 0 |
| 2024-09-20 | 3 | 0 | PUT | 0 | 0 | 190.41 | TRUE | 0 | 0 |
| 2024-09-20 | 4 | 0 | PUT | 0 | 0 | 161.78 | TRUE | 0 | 0 |
| 2024-09-20 | 5 | 0 | PUT | 0 | 0 | 226.94 | TRUE | 0 | 0 |
| 2024-12-20 | 0.5 | 0 | CALL | 0 | 0 | 85.58 | TRUE | 0 | 0 |
| 2024-12-20 | 1 | 0 | CALL | 0 | 0 | 253.94 | TRUE | 0 | 0 |
| 2024-12-20 | 1.5 | 0 | CALL | 0 | 0 | 92.26 | FALSE | 0 | 0 |
| 2024-12-20 | 2 | 0.1 | CALL | 30 | 0 | 84.76 | FALSE | 0.1 | 0 |
| 2024-12-20 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-12-20 | 1 | 0 | PUT | 0 | 0 | 81.1 | FALSE | 0 | 0 |
| 2024-12-20 | 1.5 | 0 | PUT | 0 | 0 | 89.91 | TRUE | 0 | 0 |
| 2024-12-20 | 2 | 0 | PUT | 0 | 0 | 100.45 | TRUE | 0 | 0 |
| 2024-12-20 | 3 | 0 | PUT | 0 | 0 | 114.63 | TRUE | 0 | 0 |
| 2024-12-20 | 4 | 0 | PUT | 0 | 0 | 232.23 | TRUE | 0 | 0 |
Latest RIGL Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $0.6924 |
| Jun 13, 2022 7:59 PM EST | 200 | $0.6924 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.6924 |
| Jun 13, 2022 7:59 PM EST | 500 | $0.6924 |
| Jun 13, 2022 7:59 PM EST | 850 | $0.6921 |
Rigel Pharmaceuticals, Inc (RIGL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm |
| 2019-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000021545719005836/0000215457-19-005836-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000031506619001306/0000315066-19-001306-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000031506620001146/0000315066-20-001146-index.htm |
| 2020-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000083423720006820/0000834237-20-006820-index.htm |
| 2020-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000083423720009960/0000834237-20-009960-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000090221919000369/0000902219-19-000369-index.htm |
| 2020-01-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000090221920000160/0000902219-20-000160-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000093041319000568/0000930413-19-000568-index.htm |
| 2019-04-09 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1034842/000104746919002080/0001047469-19-002080-index.htm |
| 2020-04-01 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1034842/000104746920001990/0001047469-20-001990-index.htm |
| 2020-05-01 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1034842/000104746920002759/0001047469-20-002759-index.htm |
| 2020-08-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1034842/000104746920004389/0001047469-20-004389-index.htm |
| 2018-05-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465918034498/0001104659-18-034498-index.htm |
| 2018-05-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465918037232/0001104659-18-037232-index.htm |
| 2018-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465918050532/0001104659-18-050532-index.htm |
| 2018-08-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1034842/000110465918050560/0001104659-18-050560-index.htm |
| 2018-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465918060459/0001104659-18-060459-index.htm |
| 2018-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465918064285/0001104659-18-064285-index.htm |
| 2018-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465918066323/0001104659-18-066323-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919001118/0001104659-19-001118-index.htm |
| 2019-01-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919002845/0001104659-19-002845-index.htm |
| 2019-02-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919005217/0001104659-19-005217-index.htm |
| 2019-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919011582/0001104659-19-011582-index.htm |
| 2019-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919017440/0001104659-19-017440-index.htm |
| 2019-04-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1034842/000110465919020480/0001104659-19-020480-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919027507/0001104659-19-027507-index.htm |
| 2019-05-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919029862/0001104659-19-029862-index.htm |
| 2019-05-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919031798/0001104659-19-031798-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919044305/0001104659-19-044305-index.htm |
| 2019-08-07 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1034842/000110465919044376/0001104659-19-044376-index.htm |
| 2019-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919052388/0001104659-19-052388-index.htm |
| 2019-10-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919055689/0001104659-19-055689-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919060054/0001104659-19-060054-index.htm |
| 2019-11-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919065084/0001104659-19-065084-index.htm |
| 2019-11-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919066635/0001104659-19-066635-index.htm |
| 2019-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465919073467/0001104659-19-073467-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920003446/0001104659-20-003446-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000110465920016449/0001104659-20-016449-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920026180/0001104659-20-026180-index.htm |
| 2020-04-01 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1034842/000110465920041947/0001104659-20-041947-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920056879/0001104659-20-056879-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920062621/0001104659-20-062621-index.htm |
| 2020-08-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920090262/0001104659-20-090262-index.htm |
| 2020-08-04 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1034842/000110465920090388/0001104659-20-090388-index.htm |
| 2020-10-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920113467/0001104659-20-113467-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1034842/000110465920121776/0001104659-20-121776-index.htm |
| 2018-05-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018006680/0001179110-18-006680-index.htm |
| 2018-05-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018006681/0001179110-18-006681-index.htm |
| 2018-05-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018006682/0001179110-18-006682-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007148/0001179110-18-007148-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007149/0001179110-18-007149-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007150/0001179110-18-007150-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007151/0001179110-18-007151-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007152/0001179110-18-007152-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007153/0001179110-18-007153-index.htm |
| 2018-05-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018007154/0001179110-18-007154-index.htm |
| 2018-06-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018008174/0001179110-18-008174-index.htm |
| 2018-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018008176/0001179110-18-008176-index.htm |
| 2018-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm |
| 2018-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018010636/0001179110-18-010636-index.htm |
| 2018-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm |
| 2018-08-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm |
| 2018-09-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm |
| 2018-09-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm |
| 2018-09-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm |
| 2018-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000931/0001179110-19-000931-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000932/0001179110-19-000932-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000933/0001179110-19-000933-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000934/0001179110-19-000934-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000935/0001179110-19-000935-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000936/0001179110-19-000936-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000938/0001179110-19-000938-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000939/0001179110-19-000939-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019000940/0001179110-19-000940-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004205/0001179110-19-004205-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004206/0001179110-19-004206-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004207/0001179110-19-004207-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004208/0001179110-19-004208-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004209/0001179110-19-004209-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004210/0001179110-19-004210-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004211/0001179110-19-004211-index.htm |
| 2019-03-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004212/0001179110-19-004212-index.htm |
| 2019-04-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004736/0001179110-19-004736-index.htm |
| 2019-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019004740/0001179110-19-004740-index.htm |
| 2019-05-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006694/0001179110-19-006694-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006698/0001179110-19-006698-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006699/0001179110-19-006699-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006700/0001179110-19-006700-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006701/0001179110-19-006701-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006702/0001179110-19-006702-index.htm |
| 2019-05-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006703/0001179110-19-006703-index.htm |
| 2019-11-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011701/0001179110-19-011701-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011937/0001179110-19-011937-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011938/0001179110-19-011938-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011940/0001179110-19-011940-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011942/0001179110-19-011942-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011944/0001179110-19-011944-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011946/0001179110-19-011946-index.htm |
| 2019-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911019011948/0001179110-19-011948-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020001348/0001179110-20-001348-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020001349/0001179110-20-001349-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020001350/0001179110-20-001350-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020001351/0001179110-20-001351-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006129/0001179110-20-006129-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006130/0001179110-20-006130-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006131/0001179110-20-006131-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006132/0001179110-20-006132-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006133/0001179110-20-006133-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006134/0001179110-20-006134-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006135/0001179110-20-006135-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020006136/0001179110-20-006136-index.htm |
| 2020-08-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020009204/0001179110-20-009204-index.htm |
| 2020-08-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1034842/000117911020009207/0001179110-20-009207-index.htm |
| 2019-11-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000131924419000084/0001319244-19-000084-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1034842/000131924420000054/0001319244-20-000054-index.htm |
| 2018-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837018006758/0001558370-18-006758-index.htm |
| 2018-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837018008624/0001558370-18-008624-index.htm |
| 2019-02-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1034842/000155837019001310/0001558370-19-001310-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837019004244/0001558370-19-004244-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837019007232/0001558370-19-007232-index.htm |
| 2019-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837019009974/0001558370-19-009974-index.htm |
| 2020-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1034842/000155837020001624/0001558370-20-001624-index.htm |
| 2020-05-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837020005179/0001558370-20-005179-index.htm |
| 2020-08-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837020009154/0001558370-20-009154-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1034842/000155837020012838/0001558370-20-012838-index.htm |
| 2019-03-20 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1034842/999999999719001548/9999999997-19-001548-index.htm |
| 2020-01-16 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1034842/999999999720000137/9999999997-20-000137-index.htm |
| 2020-01-16 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1034842/999999999720000138/9999999997-20-000138-index.htm |
| 2020-01-16 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1034842/999999999720000139/9999999997-20-000139-index.htm |
| 2020-02-05 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1034842/999999999720000517/9999999997-20-000517-index.htm |
| 2020-02-18 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1034842/999999999720000741/9999999997-20-000741-index.htm |
| 2020-04-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1034842/999999999720002114/9999999997-20-002114-index.htm |
| 2020-04-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1034842/999999999720002115/9999999997-20-002115-index.htm |
Rigel Pharmaceuticals, Inc (RIGL) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals, Inc (RIGL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 31%Institutional Ownership: 8526%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-07-02 | Anne-Marie Duliege | EVP & Chief Medical Officer | Sell | 5,000.00 | 2.79 | 13,932.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018009506/0001179110-18-009506-index.htm |
| 2018-09-04 | Anne-Marie Duliege | EVP & Chief Medical Officer | Sell | 16,500.00 | 3.51 | 57,860.55 | 0.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm |
| 2018-09-17 | Anne-Marie Duliege | EVP & Chief Medical Officer | Sell | 115,500.00 | 3.50 | 404,250.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm |
| 2018-08-23 | Eldon C. III Mayer | EVP & Chief Commercial Officer | Buy | 100,000.00 | 2.82 | 282,320.00 | 115,000.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018010936/0001179110-18-010936-index.htm |
| 2018-09-17 | Anne-Marie Duliege | EVP & Chief Medical Officer | Buy | 115,500.00 | 2.54 | 293,370.00 | 115,500.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm |
| 2018-09-04 | Anne-Marie Duliege | EVP & Chief Medical Officer | Buy | 16,500.00 | 2.54 | 41,910.00 | 16,500.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011179/0001179110-18-011179-index.htm |
| 2018-09-10 | Eldon C. III Mayer | EVP & Chief Commercial Officer | Buy | 50,000.00 | 3.28 | 164,210.00 | 165,000.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm |
| 2018-08-17 | RAUL R RODRIGUEZ | CEO, President | Buy | 114,000.00 | 2.63 | 300,002.40 | 173,519.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018010749/0001179110-18-010749-index.htm |
| 2018-09-11 | Eldon C. III Mayer | EVP & Chief Commercial Officer | Buy | 50,000.00 | 3.23 | 161,340.00 | 215,000.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011343/0001179110-18-011343-index.htm |
| 2018-09-17 | Anne-Marie Duliege | EVP & Chief Medical Officer | Buy | 37,500.00 | 2.11 | 79,125.00 | 37,500.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018011567/0001179110-18-011567-index.htm |
| 2019-05-22 | Dean L Schorno | EVP &Chief Financial Officer | Buy | 46,726.00 | 2.13 | 99,573.11 | 46,726.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm |
| 2019-05-22 | Dean L Schorno | EVP &Chief Financial Officer | Buy | 3,274.00 | 2.13 | 6,971.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911019006608/0001179110-19-006608-index.htm |
| 2018-10-12 | Nelson Cabatuan | Principal Accounting Officer | Sell | 10,000.00 | 3.12 | 31,200.00 | 58.00 | https://www.sec.gov/Archives/edgar/data/1034842/000117911018012211/0001179110-18-012211-index.htm |